Hypertrophic Cardiomyopathy

Barron1

  • 1Department of Internal Medicine, Section of Cardiology, Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA.

Insights

Hypertrophic cardiomyopathy (HCM) presents variably, with treatments ranging from medical therapy for mild cases to pacing or surgery for severe obstructive forms. Advanced disease may warrant earlier cardiac transplantation consideration.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) exhibits a wide spectrum of clinical severity, from asymptomatic to severe disease.
  • Medical therapy is effective for mild to moderate HCM but offers limited benefit and potential complications in severe cases.
  • Symptomatic patients with outflow tract gradients may initially benefit from pacing, but long-term efficacy is often limited by disease progression.

Purpose of the Study:

  • To review the clinical presentation and management strategies for hypertrophic cardiomyopathy (HCM).
  • To discuss the efficacy and limitations of various treatment modalities, including medical therapy, pacing, surgery, and transplantation.
  • To provide guidance on selecting appropriate interventions based on disease severity and patient factors.

Main Methods:

  • Review of existing literature on hypertrophic cardiomyopathy (HCM) management.
  • Analysis of treatment outcomes for medical, interventional, and surgical approaches.
  • Discussion of prognostic indicators and criteria for advanced therapies.

Main Results:

  • Medical therapy is beneficial for mild/moderate HCM but less effective and potentially complicating for severe disease.
  • Atrioventricular sequential pacing can alleviate symptoms in some patients with obstructive HCM, but benefits are often temporary.
  • Surgical myotomy-myectomy outcomes are surgeon-dependent, while cardiac transplantation is a consideration for end-stage disease.

Conclusions:

  • Treatment decisions for hypertrophic cardiomyopathy (HCM) must be individualized based on clinical presentation and disease severity.
  • While medical therapy and pacing offer symptomatic relief, advanced or end-stage HCM may necessitate surgical intervention or cardiac transplantation.
  • Early consideration of cardiac transplantation in severe HCM with left ventricular dysfunction is crucial for improved outcomes.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...